Biocon Limited has achieved a significant milestone in its sustainability journey with an improved S&P Global ESG Score of 69 for 2024, a 6-point increase from the previous year. This places Biocon in the 98th percentile among global biotechnology industry peers, reaffirming its leadership in Environmental, Social, and Governance (ESG) practices.

Building upon its robust ESG governance structure, Biocon has consistently integrated sustainability principles into its strategic development and daily operations. The latest S&P Global scores reflect the Company’s progress across all three ESG dimensions.

Score Breakdown

– Environmental: Scored 76 (up from 69), driven by strong policies on energy efficiency, water management, and climate action.

– Social: Scored 74 (up from 62), reflecting advancements in human capital management and patient-centric initiatives.

– Governance: Scored 62, demonstrating unwavering commitment to ethical business practices and transparency.

Recognition and Commitment

The S&P Global ESG Score measures a company’s performance on and management of material ESG risks, opportunities, and impacts informed by a combination of company disclosures, media and stakeholder analysis, modeling approaches, and in-depth company engagement via the S&P Global CSA. The assessment serves as a crucial reference for stakeholders in making informed business and investment decisions.

Biocon’s ESG score has seen an impressive increase from 52 in 2022 to 69 in 2024, in S&P Global’s Corporate Sustainability Assessment (CSA), emphasizing our dedication to driving positive change.

Advancing Transparency and Sustainability

Biocon’s high disclosure levels—90% of required and 97% of additional disclosures—highlight its dedication to open and ethical practices. This transparency has earned the trust of stakeholders and positioned Biocon as a role model in ESG governance.

Visit our Responsibility page to learn more about Biocon’s ESG initiatives and impact.

Hope. Now within reach

Meeting unmet patient needs

Research Saves Lives

First to Launch an Interchangeable Biosimilar in U.S.

Biocon Enters Prestigious Dow Jones Sustainability Emerging Markets Index

Biocon Certified as a Great Place to Work® : DEI